Atoris Pancreatic Carcinoma Side Effect Reports
The following Atoris Pancreatic Carcinoma side effect reports were submitted by healthcare professionals and consumers.
This information will help you understand how side effects, such as Pancreatic Carcinoma, can occur, and what you can do about them.
A side effect could appear soon after you start Atoris or it might take time to develop.
|Pancreatic Carcinoma, Hepatotoxicity, Liver Disorder|
This Pancreatic Carcinoma side effect was reported by a physician from HUNGARY. A patient (weight:NA) experienced the following symptoms/conditions: hyperlipidaemia,type 2 diabetes mellitus,gastrooesophageal reflux disease. The patient was prescribed Atoris (dosage: NA), which was started on Jan 19, 2010. Concurrently used drugs:
Atoris Pancreatic Carcinoma Causes and Reviews
The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include
- Long-term diabetes
- Chronic pancreatitis
- Certain hereditary disorders
Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it.
Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.
NIH: National Cancer Institute
Atoris Pancreatic Carcinoma ReviewsNo reviews submitted yet, check in later.